Global Edition
Global Edition
UK Edition
EU Edition
US Edition

Understand the story, not the spin.

Markets

FDA approves GSK’s Nelkarmi for ALK-positive lung cancer

Published 18 November 2026 · All stories from this day

The U.S. Food and Drug Administration granted accelerated approval on November 17 to GSK’s Nelkarmi, or neladalkib, for adults with advanced ALK-positive non-small cell lung cancer whose disease progressed after specified earlier treatments. The decision gives eligible patients another targeted treatment option, while approval is based on tumor responses rather than evidence that the drug helps patients live longer.

The authorization covers two groups: patients whose only prior ALK inhibitor was alectinib, and patients who received at least two ALK inhibitors as well as platinum-based chemotherapy. The FDA’s decision was based on ALKOVE1, a Phase 1/2 trial in which patients received neladalkib. Because it is an accelerated approval, continued approval may depend on confirmatory evidence of clinical benefit.

Among 67 trial participants previously treated only with alectinib, 49% had tumors shrink. Of those responders, 76% had responses lasting at least six months and 52% had responses lasting at least 12 months. In a group of 155 patients previously treated with at least two ALK inhibitors and platinum-based chemotherapy, 32% had tumor responses; among responders, 69% lasted at...

Now playing
0:00 / 0:00